Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
äŒæ¥ã³ãŒãACON
äŒç€ŸåAclarion Inc
äžå Žæ¥Apr 22, 2022
æé«çµå¶è²¬ä»»è
ãCEOãNess (Brent)
åŸæ¥å¡æ°6
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 22
æ¬ç€Ÿæåšå°8181 Arista Place
éœåžBROOMFIELD
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·80021
é»è©±çªå·18332752266
ãŠã§ããµã€ãhttps://aclarion.com/
äŒæ¥ã³ãŒãACON
äžå Žæ¥Apr 22, 2022
æé«çµå¶è²¬ä»»è
ãCEOãNess (Brent)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã